Curious about a compound or a headline? Find a clear explanation, follow the original research, and see which questions remain open.
SlimWithPeps / Research notesRead SUMMIT’s tirzepatide heart-failure results: the combined endpoint, separate death counts, health-status score and current US label context.
Read the article53 articles
Read SUMMIT’s tirzepatide heart-failure results: the combined endpoint, separate death counts, health-status score and current US label context.
Understand ESSENCE’s two liver-biopsy endpoints, the 72-week interim findings and what Wegovy’s accelerated MASH approval does and does not establish.
What human blood studies reveal about collagen peptide absorption, and why circulating fragments do not automatically establish skin or joint benefits.
Read peptide trials more clearly: distinguish change from baseline, placebo-group change and the treatment comparison, using STEP 1 as a worked example.
Understand SELECT’s 20% cardiovascular result, the absolute event proportions, the combined endpoint and who the semaglutide trial actually studied.
Explore the small GHRP-6 human pharmacokinetic study, why distribution and elimination half-lives differ, and why neither establishes a treatment schedule.
Understand weight regain after tirzepatide, the two baselines in SURMOUNT-4, and why a percentage of body weight differs from a percentage of weight lost.
Peptides and steroids are different chemical categories. Learn why that distinction cannot establish product safety, approval, effectiveness or hormonal effects.
Understand the STEP 8 semaglutide–liraglutide comparison, percentage-point differences, treatment discontinuation and the limits of applying averages.
Learn how to read peptide endotoxin results, reporting limits, units and method suitability—and why a passing result does not establish sterility.
Understand tirzepatide’s DXA findings, the difference between lean tissue and muscle, and why percentages of weight loss need careful interpretation.
Compare collagen and whey muscle research, from six-day protein synthesis measurements to year-long outcomes, without confusing one result for another.
Understand SURMOUNT-OSA’s breathing-event results, the role of PAP in the trials, and what tirzepatide’s sleep-apnea approval does and does not mean.
Explore how SNAC helps oral semaglutide absorption, what food-effect studies measured, and why tablet evidence cannot validate a different formulation.
Read FLOW’s semaglutide kidney results, distinguish relative risk from percentage points, and see how new mechanism research fits the clinical evidence.
Understand what Forzinity’s elamipretide approval covers, the limits of its early trials, and what the new confirmatory study is designed to establish.
Compare collagen joint-pain trials, placebo-adjusted results and registry details to understand why symptom relief does not establish cartilage repair.
Understand peptide immunogenicity through tirzepatide trial data: antibody detection, clinical effects, safety findings and limits of cross-drug comparisons.
Learn which peptides original Matrixyl and Matrixyl 3000 contain, what wrinkle trials tested, and how to match a cosmetic claim to its formulation.
Read the oxytocin autism trial results and a 2026 placebo analysis, with clear explanations of treatment effects, formulation differences and limits.
Cagrilintide and CagriSema are different interventions. Learn which trial produced each result, how analyses differ, and what FDA says about cagrilintide.
Read survodutide’s MASH trial accurately: why improvement without worsening fibrosis differs from scar reversal, and what its response rates measure.
What STEP 1 and STEP 4 found after semaglutide withdrawal, why their percentages differ, and what group averages cannot predict for an individual.
Explore the human Argireline wrinkle trial, skin-penetration research and cosmetic claims, with a clear explanation of what the evidence cannot establish.
What small human GHRP-2 studies found about appetite, what their meal-intake results cannot prove, and how FDA safety concerns change the context.
MK-677 is not a peptide. Explore ibutamoren’s human trial evidence, why fat-free mass differs from strength, and its FDA status and safety concerns.
Understand Vyleesi’s approved use, the bremelanotide trial outcomes, and why an online PT-141 preparation does not inherit a prescription product’s approval.
Explore a 2026 kisspeptin-10 study in healthy men, why timing affected hormone responses, and which fertility and long-term treatment questions remain open.
Read Melanotan II safety reports in context: serious events, uncertain risk rates, and why an apparent tanning effect does not establish product safety.
Understand Scenesse’s approved EPP indication, the pain-free light-exposure endpoint, and why afamelanotide evidence does not establish a cosmetic tanning use.
Examine the LL-37 venous-ulcer trial, its overall negative finding and exploratory subgroup result, and why topical research does not validate injected products.
Explore AOD-9604 weight-loss research, the larger negative obesity trial, and why changes within a treatment group do not prove a treatment effect.
Learn what recent epitalon cell research measured, why telomere changes do not prove longer human life, and why epithalamin is a separate substance.
Read a Semax stroke-rehabilitation study in context: participant groups, BDNF measurements, functional outcomes and limits on cognitive-enhancement claims.
Examine a Selank anxiety study comparing 62 patients, the difference between similar results and proven equivalence, and the limits of abstract-only evidence.
Compare two small DSIP insomnia studies, their different sleep outcomes, and why a sleep-inducing name does not establish a reliable insomnia treatment.
Read the human ipamorelin trial behind the claims: what researchers tested, the nonsignificant result, and why its safety findings need context.
Understand the history of GEREF, its withdrawn approvals, and why an FDA finding about withdrawal does not approve a compounded sermorelin product.
KPV research includes human-derived cells and mouse colitis models. Learn why these are not human treatment trials and which questions remain open.
Separate human MOTS-c measurements during exercise from mouse treatment experiments, and understand why neither proves an injectable product benefits people.
Explore the TESTS sepsis trial of thymosin alpha-1, its published correction, and why an overall result differs from an exploratory subgroup claim.
Understand how compounded semaglutide differs from an approved medicine, why salt forms matter, and what to clarify with a prescriber or pharmacist.
Tesamorelin has a specific approved medical use. Learn why that differs from a general weight-loss claim and how to read the EGRIFTA WR label.
TB-500 and full-length thymosin beta-4 are not interchangeable research labels. Learn how to check which molecule a human study actually tested.
Explore what early CJC-1295 trials measured, why increased GH and IGF-1 do not prove clinical benefit, and what safety questions remain.
A closer look at a collagen-peptide skin trial: the studied formulation, measured outcomes, participant dropouts and limits of a positive result.
Compare the actual GLOW and KLOW labels, understand what KPV adds, and learn why ingredient studies cannot establish a blend’s clinical benefits.
Learn what a peptide COA can show about identity, purity, content and microbiological testing—and how to spot the questions a report leaves unanswered.
Understand the triple receptor agonist, its investigational status, and the questions to ask about new trial results.
Why promising experiments, small human reports and established clinical evidence are different things.
A closer look at topical copper-peptide evidence, study endpoints, and why skin-care findings do not validate injections.
What the SURMOUNT-5 trial found, which population it studied, and why averages are not individual predictions.
Peptides connect amino acids, but the word alone tells you little about a product’s purpose, evidence or approval.
Try a compound name or a broader topic.
